



References

1. Albietz JM. Prevalence of dry eye subtypes in clinical optometry practice. *Optom Vis Sci* 2000; 77: 357-363.
2. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: 25 year review. *Cornea* 2000; 19:644–9.
3. Tseng SCG, Tsubota K. Important concepts for treating ocular surface and tear film disorders. *Am J Ophthalmol* 1997; 124: 825-835.
4. Lemp MA. Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes. *CLAO J* 1995; 21: 221-232.
5. Bron AJ. Diagnosis of dry eye. *Surv Ophthalmol*. 2001; 45 (Suppl 2): S217-23.
6. Pflugfelder SC. The anti-inflammatory therapy of dry eye. *Am J Ophthalmol* 2004; 137:337-42.
7. Power WJ, Mullaney P, Farrell M, Collum I.M. Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjogren's syndrome. *Cornea* 1993; 12:507-11.
8. Nelson JD, Helms H, Fiscella R, Southwell Y, Hirsch JD. A new look at dry eye disease and its treatment. *Adv Ther*. 2001; 17:84-93.
9. Toledo AR, Chandler JW and Buffam FV. Lacrimal system: Dry eye state and other conditions: in Pods S and Yonoff M: *Text of ophthalmology*. Mosby, London, 1994: 14:1-14.30.
10. Snell RS and Lemp MA. *Clinical anatomy of the eye*. USA, Malen, Blackwell science. 1998; 2nd edition. 132-214.
11. Bron AJ, Tripathi RC. and Tripathi BJ. *Wolff's anatomy of the eye and orbit*. Chapman & Hall medical. 1997; 8th edition, 51-85.



12. Kanski JJ. Clinical ophthalmology A systemic approach. Butterworth-Heinemann. Reed Educational and professional publishing Ltd; 2004; 78-82.
13. Lemp MA. And Wolfly DE. The lacrimal apparatus. In: Adler's physiology of the eye. HRT W.M. Mosby. 1992; 9th edition.
14. Thomas AW, Thomas JL and Grand MG. "Dry eye states" in basic of clinical science course. 1998.
15. Lamberts DW. Physiology of the tear film. In: Samolin G., Thoft RA 2nd edition. The cornea, scientific foundations and clinical practice. Baston / Tronto, Little, Brown and company.1997.
16. Bron AJ. Non-Sjögren's dry eye: pathogenesis, diagnosis and animal models. In: Sullivan DA, ed. Lacrimal Gland, Tear Film and Dry Eye Syndromes. New York: Plenum Press, 1994; 471-488.
17. Stern ME, Gao J, Siemasko KF. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res 2004;78:409 – 16.
18. Mathers WD. Why the eye becomes dry: a cornea and lacrimal gland feedback model functional unit concept. CLAOJ 2000; 26:159-165.
19. Tiffany JM. The role of meibomian secretion in the tears. Trans Ophthalmol Soc UK 1985; 104: 396-401.
20. Smolin G. The role of tears in the prevention of infection. Int Ophthalmol Clin 1987; 27: 25-26.
21. Marquardt R. Histological studies of goblet cell count in the human conjunctiva. In: Holly FJ, ed. The Preocular Tear Film in Health, Disease and Contact Lens Wear. Lubbock, Texas: Dry Eye Institute INC, 1986; 312-318.
22. Watanabe H, Fabrincant M, Tisdale AS, Spurr-Michaud SJ, Linberg K, Gipson IK. Human corneal and conjunctival epithelia



- produce a mucin-like glycoprotein for the apical surface. *Invest Ophthalmol Vis Sci* 1995; 36: 337-344.
23. Liotet S, Van Bijsterveld OP, Kogbe O, Laroche L. A new hypothesis on tear film stability. *Ophthalmologica* 1987; 195: 119-124.
24. Kojima T, Ishida R, Dogru M. A new noninvasive tear stability analysis system for the assessment of dry eyes. *Invest Ophthalmol Vis Sci* 2004;45:1369 –1374.
25. King-Smith PE, Fink BA, Fogt N, Nichols KK, Hill RM, Wilson GS. The thickness of the human precorneal tear film: evidence from reflection spectra. *Invest Ophthalmol Vis Sci*: 2000; 41: 3348-3359.
26. Bron AJ, Mengher LS, Davey CC. The normal conjunctiva and its response to inflammation. *Trans Ophthalmol Soc UK* 1985; 104: 424-435.
27. Wanko T, Lioyd B, Matthews J. The fine structure of the human conjunctiva in the perilimbal zone. *Invest Ophthalmol Vis Sci* 1994; 3: 285-301.
28. Huang AWJ, Tseng SCG. Corneal epithelial wound healing in the absence of limbal epithelium. *Invest Ophthalmol Vis Sci* 1991; 32: 96-105.
29. Lemp MA, Mathers WD. Corneal epithelial cell movement in humans. *Eye* 1989; 3: 438- 445.
30. Puangsricharen V, Tseng SCG. Cytologic evidence of corneal diseases with limbal stem cell deficiency. *Ophthalmolgy* 1997; 102: 1476-1485.
31. Nakamura Y, Sotozono C, Kinoshita S. Inflammatory cytokines in normal human tears. *Curr Eye Res* 1998; 17: 673-676.



32. Baudouin C, Brignole F, Becquet F, Pisella PJ, Goguel A. Flow cytometry in impression cytology specimens. A new method for evaluation of conjunctival inflammation. *Invest Ophthalmol Vis Sci* 1997; 38: 1458-1464.
33. Rocha EM, Wickham LA, da Silveira LA. Identification of androgen receptor protein and 5 α phareductase mRNA in human ocular tissues. *Br J Ophthalmol* 2000; 84: 6-84.
34. Sullivan DA, Krenzer KL, Sullivan BD, Tolls DB, Toda I, Dana MR. Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency? *Invest Ophthalmol Vis Sci* 1999; 40: 1261-1265.
35. Chia EM, Mitchell P, Rochtchina E, Lee AJ, Maroun R, Wang JJ. Prevalence and association of dry eye syndrome in an older population: The Blue Mountain Eye Study. *Clin Exp Ophthalmol*. 2003; 31:229-232.
36. Moss SE, Klein BE. Incidence of dry eye in an older population. *Arch Ophthalmol*. 2004; 122:369-373.
37. Elkon B. Apotosis and autoimmunity. *J Rheum* 1997; 24: 6-7.
38. Stern ME, Beuerman RW, Fox R, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye; the interaction between the ocular surface and lacrimal glands. *Cornea*. 1998; 17:584-589.
39. Pepose JS, Akata RF, Pflugfelder SC, Voigt W. Mononuclear cell phenotypes and immunoglobulin gene rearrangement in lacrima! gland biopsies from patients with Sjogren's syndrome. *Ophthalmology*. 1990; 97:1599-1605.
40. Damato BE, Allan D, Murray SB, Lee WR. Senile atrophy of the human lacrimat gland: the contribution of chronic inflammatory disease. *Br J Ophthalmol*.1984; 68:P74-680.



41. Stern ME, Gao J, Schwalb TA. Conjunctival T-cell subpopulations in Sjogren's and non-Sjogren's patients with dry eye. *Invest Ophthalmol Vis Sci* 2002; 43:2609–14.
42. Hikichi T, Yoshida A, Tsubota K. Lymphocytic infiltration of the conjunctiva and the salivary gland in Sjogren's syndrome [letter]. *Arch Ophthalmol*.1993; 111:21-22.
43. Tsubota K, Fujihara T, Saito K, Takeuchi T. Conjunctival epithelium expression of HLA-DR in dry eye patients. *Ophthalmologica* 1999; 213:16-19.
44. Farris RL. Contact lenses and dry eye. *Int Ophthalmol Clin* 1991; 31: 83-90.
45. McMonnies C. Contact lens-related tear deficiency. *Problems in Optometry* 1990; 2: 584-598.
46. Dogru M, Tsubota K. Clinical dry eyes. *The Ocular Surface* 2004;2:1– 8.
47. Nelson JD. Diagnosis and treatment of dry eye: A clinical perspective. *Cornea* 2000; 19: S108.
48. Nichols KK, Begley CG, Caffery B, Jones LA. Symptoms of ocular irritation in patients diagnosed with dry eye. *Optom Vis Sci* 1999; 76: 838-844.
49. McMonnies CW, Ho A. Responses to a dry eye questionnaire from a normal population. *J Am Optom Assoc* 1987; 58: 588-591.
50. Walt JG, Rowe MM, Stern KL. Evaluating the functional impact of dry eye: the Ocular Surface Disease Index. *Drug Inf J* 1997; 31: 1436.
51. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis B. Reliability and validity of the Ocular Surface Disease Index. *Arch Ophthalmol* 2000; 118: 615-621.



52. Cho P. Stability of the precorneal tear film: a review. *Clin Exp Optom* 1991; 74: 19-25.
53. Nally L, Ousler III GW, Albelson MA. Ocular discomfort and tear film break-up time in dry eye patients: a correlation. *Invest Ophthalmol Vis Sci* 2000 Suppl; 41: S274.
54. Golding TR, Brennan NA. Diagnostic accuracy and intercorrelation of clinical tests for dry eye. *Invest Ophthalmol Vis Sci* 1993; 34: 823.
55. Greiner JV, Finnemore VM, Exford JM, Herman JP, Glonek T, Bueno EA, Korb D. Effects of fluorescein instillation methods on the stability of the tear film lipid layer. *Cornea* 2000; 19 Suppl: S90.
56. Feenestra PG, Tseng SCG. Comparison of fluorescein and rose Bengal staining. *Ophthalmology* 1992; 99: 605-617.
57. Tabery H. Dual appearance of Fluorescein staining in vivo of diseased human corneal endothelium. A non-contact photomicrographic study. *Br J Ophthalmol* 1992; 76: 43-44.
58. Chodash J, Dix RD, Howell RC, Stroop WG, Tseng SC. Staining characteristics and antiviral activity of sulphorodamine B and lissamine green B. *Invest Ophthalmol Vis Sci* 1996; 35: 1046-1058.
59. Van Bijsterveld OP. Diagnostic tests in the sicca syndrome. *Arch Ophthalmol* 1969; 82:10-14.
60. Bron AJ. The Doyne Lecture: Reflections on the tears. *Eye* 1997; 11: 583-602.
61. Catania LJ. Primary Care of Anterior Segment. Norwalk, Connecticut: Appleton and Lange, 1995.
62. Nelson JD. Diagnosis of keratoconjunctivitis sicca. *Int Ophthalmol Clin* 1994; 34: 36-56.



63. Gilbard JP, Farris RL. Tear osmolarity and ocular surface disease in keratoconjunctivitis sicca. *Arch Ophthalmol* 1979; 97: 1642-1648.
64. Little SA, Bruce AS. Repeatability of phenol-red and tear thinning time tests for tear film function. *Clin Exp Optom* 1994; 77:64-68.
65. Schirmer O. Studien zur physiologie der tranenabsonderung und tranenabfuhr. *Graefe's Arch Clin Exp Ophthalmol* 1903; 56:197-291.
66. Jones LT. The lacrimal secretory system and its treatment. *Am J Ophthalmol* 1966; 62:47-60.
67. Nelson JD. Electrolytes in 'artificial tears' mimic human tears, renew dry eyes. *Ocular Surgery News* 1994; 5: 39-41.
68. Hamano H, Hori M, Hamano T. A new method for measuring tears. *CLAOJ* 1983; 9: 281-289.
69. Goren MB, Goren SB. Diagnostic tests in patients with symptoms of keratoconjunctivitis sicca. *Am J Ophthalmol* 1988; 106: 570-574.
70. Patel S, Farrell J, Blades KJ, Grierson DJ. The value of a phenol red impregnated thread for differentiating between the aqueous and non-aqueous tear deficient dry eye. *Ophthal Physiol Opt* 1998; 18: 471-476.
71. Khurana AK, Chaudhary R, Ahluwalia BK, Gupta S. Tear film profile in dry eye. *Acta Ophthalmol (Copenh)* 1991; 69: 79-86.
72. Höh H, Schirra F, Kienecker C, Ruprecht KW. Lid-parallel conjunctival fold (LIPCOF) and dry eye: a diagnostic tool for the contactologist. *Contactologica* 1995; 17E: 104-117.
73. Mackie IA, Seal DV. The questionably dry eye. *Br J Ophthalmol* 1981; 65: 2-9.
74. Nelson JD. Simultaneous evaluations of tear turnover and corneal epithelial permeability by fluorophotometry in normal subjects and



- patients with keratoconjunctivitis sicca (KCS). *Trans Am Ophthalmol Soc* 1995; 93: 709-753.
75. Afonso AA, Monroy D, Stern ME, Feuer WJ, Tseng SC, Pflugfelder SC. Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. *Ophthalmology* 1999; 106: 803-810.
76. Vitali C, Moutsopoulos HM, Bombardiere S. The European Community Study Group on Diagnostic Criteria for Sjögren's Syndrome. *Ann Rheum Disease* 1994; 53: 637-647.
77. Foulks GN. The now and future therapy of non-Sjogren's dry eye. *Adv Exp Med Biol* 1998; 438:959– 64.
78. Tsubota K, Nakamori K. Dry eyes and video display terminals. *N Engl J Med* 1993; 328:584.
79. Mathers WD, Lane JA. Meibomian gland lipids, evaporation, and tear film stability. *Adv Exp Med Biol* 1998; 438:349– 60.
80. Foulks GN. Management of meibomian glands disease. In: Tiffany J, editor. *The meibomian glands: secretion, pathology and contact lens problems*. Lisse, The Netherlands: Swets & Zeitlinger Publishers; 2003.
81. Dougherty JM, McCulley JP, Silvany RE, Meyers DR. The role of tetracycline in chronic blepharitis: inhibition of lipase production in staphylococci. *Invest Ophthalmol Vis Sci* 1991; 32:2970– 5.
82. Calonge M. The treatment of dry eye. *Surv Ophthalmol* 2001; 45(suppl 2): S227– 39.
83. Gilbard JP. Human tear film electrolyte concentrations in health and dry-eye disease. *Int Ophthalmol Clin* 1994; 34:27 – 36.
84. Holly FJ, Lamberts DW. Effect of nonisotonic solutions on tear film osmolality. *Invest Ophthalmol Vis Sci* 1981; 20:236– 45.



85. Tsubota K. New approaches to dry eye therapy. *Int Ophthalmol Clin* 1994; 34:115– 28.
86. Murube J, Murube E. Treatment of dry eye by blocking the lacrimal canaliculi. *Surv Ophthalmol* 1996; 40: 463– 80.
87. Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. *Am J Ophthalmol* 2001; 131:30–6.
88. Will DV, McNally LM, Roth RE. Pyogenic granuloma complicating Parasolm (Odyssey™) silicone punctual plug occlusion: a series review. *Invest Ophthalmol Vis Sci* 2000; 41:S69.
89. Yen MT, Monroy D, Pflugfelder SC. Punctal occlusion decreases tear production, clearance, and ocular surface sensation. *Invest Ophthalmol Vis Sci* 1999; 40:S980.
90. Mathers WD, Dolney AM. Objective demonstration of tear stimulation with oral pilocarpine in dry eye patients. *Invest Ophthalmol Vis Sci* 2000; 41:S60.
91. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. *Arthritis Rheum* 2002; 46:748– 54.
92. Gilbard JP, Rossi SR, Heyda KG, Dartt DA. Stimulation of tear secretion by topical agents that increase cyclic nucleotide levels. *Invest Ophthalmol Vis Sci* 1990; 31:1381–8.
93. Li Y, Kuang K, Yerxa B, Wen Q, Rosskoth H, Fischbarg J. Rabbit conjunctival epithelium transports fluid, and P2Y2 (2) receptor agonists stimulate Cl(-) and fluid secretion. *Am J Physiol Cell Phys* 2001; 281:C595–602.
94. Foulks G, Sall K, Greenberg M. Phase 2 dose ranging efficacy trial of INS365 ophthalmic solution, a P2Y2 agonist, in patients with



- dry eye. ARVO Abstracts. Invest Ophthalmol Vis Sci 2001; 42:S713.
95. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren's syndrome. *Ophthalmology* 1999; 106:811 – 6.
96. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporin treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. *Arch Ophthalmol* 2000; 118:1489– 96.
97. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporin ophthalmic emulsion in moderate to severe dry eye disease: CsA Phase III Study Group. *Ophthalmology* 2000; 107:631– 9.
98. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate – to-severe dry eye disease: a dose-ranging randomized trial. *Ophthalmology* 2000; 107:967– 74.
99. Laurie D. Barber, Stephen C. Phase III Safety evaluation of cyclosporin 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. *Ophthalmology* 2005; 112:1790-1794.
100. Sullivan DA, Wickham LA, Rocha EM. Androgens and dry eye in Sjogren's syndrome. *Ann N Y Acad Sci* 1999; 876:312– 24.
101. Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. *JAMA* 2001; 286:2114– 9.
102. Horrobin DF. Essential fatty acid and prostaglandin metabolism in Sjogren's syndrome, systemic sclerosis, and rheumatoid arthritis. *Scand J Rheumatol* 1986; 61(suppl): 242 – 5.



103. Geerling G, MacLennan S, and Hartwig D. Autologous serum eye drops for ocular surface disorders. *Br J Ophthalmol* 2004; 88:1467-1474.
104. Tsubota K, Higuchi A. Serum application for treatment of ocular surface disease. *Int Ophthalmol Clin* 2000; 40:113– 22.
105. Albietz JM. Dry eye: an update on clinical diagnosis, management and promising new treatments. *Clin Exp Optom* 2001; 84: 1: 4–18.
106. Stähelin HF. The history of cyclosporin A (Sandimmune®) revisited: another point of view. *Experientia* 1996; 52:5-13.
107. Allergan, Inc., Irvine, CA 92612, U.S.A. Results from pharmacokinetic and toxicological studies by Allergan. AGN reports. 2002.
108. Pflugfelder SC, Wilhelmus KR, Osato MS. The autoimmune nature of aqueous tear deficiency. *Ophthalmology* 1986;93:1513–17.
109. Williamson J, Gibson AAM, Wilson T. Histology of the lacrimal gland in keratoconjunctivitis sicca. *Br J Ophthalmol* 1973; 57:852–8.
110. Gunduz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome. *Acta Ophthalmol* 1994; 72:438–42.
111. Laibovitz RA, Solch S, Andriano K. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. *Cornea* 1993; 12:311–23.
112. Kroemer G, Martinez A. Cytokines and autoimmune disease. ; *Clin Immunol Immunopathol* 1991; 61:275-95.
113. Tang-Liu DD, Acheampong A. Ocular pharmacokinetics and safety of cyclosporin, a novel topical treatment for dry eye. *Clin Pharmacokinet* 2005; 44:247-61.



114. Stonecipher K, Perry HD, Gross RH, Kerney DL. The impact of topical cyclosporin A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. *Curr Med Res Opin.* 2005; 21(7):1057-64.